Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Distant metastasis is the main reason for the poor prognosis of gastric cancer, and anoikis refers to the cell death caused when cells detach from the extracellular matrix or adhere in incorrect locations, playing an important role in the distant metastasis of gastric cancer.
Methods: Download the TCGA-STAD dataset and the anoikis gene set, and filter out the differentially expressed anoikis genes. Perform consensus clustering of gastric cancer samples, and conduct Weighted Gene Correlation Network Analysis (WGCNA), enrichment analysis, and immune infiltration analysis for the expression characteristics of each subtype, while also filtering the genes with differential expression between subtypes. Additionally, through COX survival analysis, identify anoikis genes related to gastric cancer prognosis and establish a nomogram. Finally, validate the differentially expressed gene CYP1B1 in vivo and in vitro through clinical samples, cell culture, and the establishment of an anoikis model.
Results: Three subtypes of gastric cancer with anoikis genes were identified, each exhibiting different expression characteristics, biological pathways, and immune cell infiltration. The abundance of activated NK cells, memory B cells, and M2 macrophages showed significant differences among the three subtypes. We screened four differentially expressed gene sets and five genes (CYP1B1, EQTN, NRXN2, TBC1D3E, TCEAL5) among the three subtypes. Through survival analysis, we identified 33 independent prognostic genes and constructed a nomogram, with calibration curves indicating good consistency. Finally, we selected CYP1B1 for experimental validation, and in vivo and in vitro experiments demonstrated that CYP1B1 is highly expressed in gastric cancer, participates in the resistance to cell death in gastric cancer cells, and promotes the invasion, migration, and tumor progression of gastric cancer cells.
Conclusion: The expression patterns of subtypes based on differentially expressed genes related to anoikis in gastric cancer vary, providing theoretical support for the future of personalized treatment for gastric cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014852 | PMC |
| http://dx.doi.org/10.1002/cam4.70907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Short-term outcomes of laparoscopic D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in distal gastric cancer patients with high body mass index.
BMC Cancer
September 2025
Department of Gastrointestinal Surgery, Affiliated Hospital of Chengde Medical University, No. 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Segmental analysis of esophageal and gastric fundus microbiome diversity in reflux esophagitis.
Folia Microbiol (Praha)
September 2025
Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China.
Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.
View Article and Find Full Text PDFClinical features of Barrett's mucosa arising in the remnant esophagus after subtotal esophagectomy and esophago-gastric anastomosis for esophageal cancer.
Esophagus
September 2025
Department of Upper Gastrointestinal Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi, 321-0293, Japan.
Background: Barrett's mucosa in the remnant esophagus (BMRE) is often identified after gastric pull-up reconstruction after esophagectomy. This study aimed to determine the clinical characteristics of BMRE and the factors that affect the development of BMRE.
Methods: The characteristics of BMRE and factors affecting its occurrence were studied in patients with subtotal esophagectomy and gastric pull-up reconstruction who survived at least 3 years after esophageal cancer surgery and who were evaluated by endoscopy.
Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.
Cancer Immunol Immunother
September 2025
Department of Gastric Surgery, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, 310022, Zhejiang, China.
Objectives: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.
Methods: Data from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group.
Gastroenteropancreatic neuroendocrine tumors: A retrospective study conducted in the Colombian Southwest.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Departamento de Medicina Interna, Servicio de Gastroenterología, Fundación Valle del Lili, Cali, Colombia. Electronic address:
Introduction And Aim: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms originating in neuroendocrine cells from the gastric mucosa and submucosa, small intestine, large intestine, rectum, and pancreas. Our aim was to describe their histopathologic, endoscopic, and clinical characteristics and the experience with these tumors at a tertiary care hospital center in the Colombian Southwest.
Materials And Methods: A retrospective, analytic, observational, and descriptive study included 93 patients diagnosed with GEP-NETs, within the time frame of 2018 and 2022.